CACLP

14/05/2026

VIEW | 🫁➡️🧠 How does severe lung injury affect the brain during critical illness?

Neurological complications, from delirium to long-term cognitive impairment, are increasingly recognized in ICU survivors, yet the mechanisms behind lung–brain interactions remain poorly understood.

🔬 Recent advances in lung and brain organoids, together with organ-on-a-chip technologies, are opening new possibilities to model complex inter-organ crosstalk, simulate clinically relevant conditions such as ARDS and ventilator-associated injury, and accelerate translational research in critical care medicine.

💡 A promising direction for understanding multiorgan dysfunction and developing future therapeutic strategies.

📚 From VIEW, an open access journal for interdisciplinary research focused on “biodiagnostics” in the field of biomaterials.

👉 Read full research https://onlinelibrary.wiley.com/doi/epdf/10.1002/VIW.20250207

13/05/2026

Business | 📊 As of 30 April 2026, a total of 86 China-listed companies related to the sector had released their 2025 annual reports, including 61 companies primarily engaged in IVD businesses and 25 companies with IVD-related operations.

Among the 61 core IVD listed companies, total revenue in 2025 reached CNY 121.71 billion. Mindray ranked first with annual revenue of CNY 33.28 billion, followed by Dian Diagnostics and Runda Medical.

For further info 👉🏻 https://en.caclp.com/industry-news/3894.html

12/05/2026

Industry | In Vitro Diagnostic Industry in China - Instruments and Reagents X——

Only 40% of hospitals currently utilize automatic blood grouping analyzers, while manual and semi-automatic testing still account for 60% of usage. However, accompanied with promotion and application of fully automated test devices, the market size of automatic blood grouping analyzers is expected to surpass manual/semi-automatic instruments within the next 3–5 years. With over 7,000 Grade II hospitals across China, the future demand for automated blood typing solutions remains significant.

For further information 👉🏻 https://en.caclp.com/industry-news/3892.html

12/05/2026

Business | What’s New in China’s Industry?

🧠 Sansure Biotech Partners with Tencent Health to Launch an AI Ecosystem for China Primary Healthcare
📍 Dynamiker Expands to Singapore
🤝 Maxim Biotechnologies and BGI Tech Forge Strategic Partnership to Build a New Pathology Industry Ecosystem
🏆 Haier Biomedical Receives Recognition from Euromonitor International

More updates here 👉🏻 https://en.caclp.com/industry-news/3893.html

08/05/2026

CACLP TALKS | Singapore’s Growing Role in Global 🌏

Why is Singapore becoming an increasingly important hub for international expansion in the industry?

In this episode, CHIA Wai Kian, Director of Guangzhou Office, Singapore Economic Development Board, shares insights into Singapore’s evolving position within the global IVD ecosystem.

Bringing together multinational corporations and innovative startups, Singapore offers:
👉 strong international regulatory recognition
👉 world-class healthcare and research resources
👉 highly skilled global talent
👉 an efficient gateway for regional and global market expansion
👉 watch the full interview: https://youtu.be/Rk5GF7l5-_Y?si=cJenWaeb3w1quYwh

Singapore is becoming a key global hub for IVD companies expanding internationally. Bringing together multinational corporations and innovative startups, the...

07/05/2026

Policy | 🌍 China’s expanded zero-tariff policy for Africa is now officially in effect.

Starting from May 1, 2026, China has extended zero-tariff treatment to all African countries with diplomatic relations with China, becoming the first major economy to provide unilateral full-coverage zero-tariff treatment across the continent.

For full official press 🔗 https://english.www.gov.cn/news/202604/28/content_WS69f0a1d7c6d00ca5f9a0aad0.html

China will expand zero-tariff treatment to all African countries that have diplomatic relations with it starting May 1, 2026, Chinese authorities announced on Tuesday.

07/05/2026

VIEW | 🧪 Could diagnosis become more accurate with fewer unnecessary procedures?

A new study explores how plasma extracellular vesicles isolated through a simple aqueous two-phase system could support more precise and accessible prostate cancer detection.

Instead of relying only on PSA, researchers combined EV biomarkers with machine learning to create a two-step diagnostic model:
👉 screening benign vs. cancer cases
👉 staging localized vs. advanced disease

Interestingly, different biomarkers played different roles depending on the diagnostic goal, with PSA helping screening, while EV markers like CD81 and PSMA showed stronger value in staging.

The approach may help reduce diagnostic errors while simplifying testing, offering a promising direction for scalable and noninvasive prostate cancer diagnostics, especially in resource-limited settings.

📚 From VIEW, an open access journal for interdisciplinary research focused on “biodiagnostics” in the field of biomaterials.

👉 Read full research https://onlinelibrary.wiley.com/doi/epdf/10.1002/VIW.20250180

06/05/2026

New Release | The Annual Report of China IVD Industry 2025 📊

The Annual Report of China Industry 2025 has been officially released during the 13th China IVD Industry Development Conference during .

Jointly edited by the China Association of In-Vitro Diagnostics , the IVD Branch of China Association for Medical Devices Industry, and IVD Industrial Development Institute of Shanghai Academy of Experimental Medicine, the report provides a comprehensive overview of the industry landscape in China.

Structured in four key sections, the report covers:
👉 Policy & Regulatory
👉 Financing & Investment Trends
👉 Industry Status & Future Outlook
👉 Opportunities & Strategies

The full report will be further explored in our upcoming webinar and featured in our report column on CACLP

Follow us for more insights.💡

05/05/2026

Industry | In Vitro Diagnostic Industry in China - Instruments and Reagents IX——

According to network data analysis, market size of China’s blood grouping analyzer was RMB 1.704 billion in 2024, and it is predicted to achieve RMB 1.89 billion in 2025. Market size of blood grouping analyzer will maintain a steady growth trend in the future.

See more 👉🏻 https://en.caclp.com/industry-news/3880.html

04/05/2026

CACLP TALKS | Unlocking China–UK Synergies in 🤝

How can China and the UK better align their strengths to drive the next wave of innovation?

In this episode, Rahul Agarwal discusses the evolving partnership between the two ecosystems, where the UK’s research and innovation capabilities meet China’s manufacturing efficiency and market scale.

The conversation explores key drivers shaping this collaboration:
👉 translating innovation into practical clinical use
👉 expanding early screening pathways
👉 responding to the demands of an aging population

With stronger policy support and growing industry linkages, China-UK cooperation is opening new pathways for faster and broader access to diagnostic solutions.

🎬 Watch the full interview: https://youtu.be/NIMYDseqO7c?si=QidLJr8UWUqbtNyv

1 like. "Talk with Rahul AGARWAL at CACLP 2026"

29/04/2026

VIEW | 🧬 are no longer just detection tools - they are becoming smarter diagnostic components.

A new review shows how antibody discovery in is moving far beyond traditional affinity and specificity, toward assay-aware design that improves real-world test performance.

With advances in single-B-cell screening, phage display, and AI-assisted design, antibodies are increasingly being engineered as part of the entire diagnostic system, not simply selected as binders.

As diagnostics become more precise, the future may depend not just on finding the right antibody, but on designing how it performs inside the test itself.

📚 From VIEW, an open access journal for interdisciplinary research focused on “biodiagnostics” in the field of biomaterials.

👉🏻 Read full research https://onlinelibrary.wiley.com/doi/epdf/10.1002/VIW.20250218